STATUS OF THE CLAIMS

In the Claims:

1. (Currently amended) A planiform transmucosal pharmaceutical administration form for release of active compound in the oral cavity, characterized in that the administration form is composed of a solid solution of the active compound

a) ~~in a~~ in phosphatidylcholine ~~fraction in which the fatty acid residues are at least 90% saturated and~~, wherein the administration form comprises at least 80% by weight of ~~the~~ phosphatidylcholine ~~fraction~~ and the fatty acid residues of the phosphatidylcholine are at least 90% saturated, or

b) in a mixture of the phosphatidylcholine ~~fraction~~ specified under a) and a copolymer composed of maleic acid and an alkyl vinyl ether, and,

where appropriate, further pharmaceutically tolerated adjuvants and additives

wherein the active compound is selected from the group consisting of epibatidine, mecamylamine, hypericin, CP-52655, bupropion, oxazolidinone compounds, befloxatones, cannabinoid receptor (CB 1) antagonist SR 141716 and salts thereof.

2. (Cancelled)

3. (Original) The administration form as claimed in claim 1, characterized in that it comprises polyvinylpyrrolidone as additive.

4. (Original) The administration form as claimed in claim 1, characterized in that the active compound is suitable for treating the abuse of addiction-inducing drugs and dependence on these drugs.

5. (Cancelled)

6. (Cancelled)

7. (Previously presented) The administration form as claimed in claim 1, characterized in that the active compound is epibatidine and/or a salt of this compound.

8. (Cancelled)

9. (Previously presented) The administration form as claimed in claim 1, characterized in that the active compound is selected from the compound group mecamylamine, hypericin, CP-52655 and bupropion and/or a salt thereof.

10. (Previously presented) The administration form as claimed in claim 1, characterized in that the active compound is selected from the group of oxazolidinone compounds and befloxatones.

11. (Original) The administration form as claimed in claim 1, characterized in that the active compound is the cannabinoid receptor (CB 1) antagonist SR 141716.

12. (Currently amended) The administration form as claimed in claim 1, characterized in that the administration form is composed of a solid solution of the active compound in phosphatidylcholine, wherein the administration form comprises at least 80% by weight of phosphatidylcholine and the fatty acid residues of the phosphatidylcholine are at least 90% saturated, ~~a phosphatidylcholine fraction in which the fatty acid residues are at least 90% saturated and the administration form comprises at least 80% by weight of the phosphatidylcholine fraction~~.

13. (Currently amended) The administration form as claimed in claim 1, characterized in that the administration form is composed of a solid solution of the active compound in a mixture of a phosphatidylcholine, wherein the administration form comprises at least 80% by weight of phosphatidylcholine and the fatty acid residues of the phosphatidylcholine are at least 90% saturated, ~~fraction in which the fatty acid residues are at least 90% saturated and the administration form comprises at least 80% by weight of the phosphatidylcholine fraction~~ and a copolymer composed of maleic acid and an alkyl vinyl ether.

14. (New) The administration form as claimed in claim 1, characterized in that when water is added to the administration form, lamellar mesophases form wherein the active compound is present in the lamellar region.

15. (New) A planiform transmucosal pharmaceutical administration form for release of active compound in the oral cavity, characterized in that the administration form is composed of a solid solution of the active compound

a) in phosphatidylcholine, wherein the administration form comprises at least 80% by weight of phosphatidylcholine and the fatty acid residues of the phosphatidylcholine are at least 90% saturated, or

b) in a mixture of the phosphatidylcholine fraction specified under a) and a copolymer composed of maleic acid and an alkyl vinyl ether, and
where appropriate, further pharmaceutically tolerated adjuvants and additives; and

wherein water is added to the solid solution of the active compound which form lamellar mesophases wherein the active compound is present in the lamellar region; and

wherein the active compound is selected from the group consisting of epibatidine, mecamylamine, hypericin, CP-52655, bupropion, oxazolidinone compounds, befloxatones, cannabinoid receptor (CB 1) antagonist SR 141716 and salts thereof.

16. (New) The administration form as claimed in claim 15, characterized in that it comprises polyvinylpyrrolidone as additive.

17. (New) The administration form as claimed in claim 15, characterized in that the active compound is epibatidine and/or a salt of this compound.

18. (New) The administration form as claimed in claim 15, characterized in that the active compound is selected from the compound group mecamylamine, hypericin, CP-52655 and

bupropion and/or a salt thereof.

19. (New) The administration form as claimed in claim 15, characterized in that the active compound is selected from the group of oxazolidinone compounds and befloxatones.

20. (New) The administration form as claimed in claim 15, characterized in that the active compound is the cannabinoid receptor (CB 1) antagonist SR 141716.